Johnson & Johnson ($JNJ) made a big move in China this week with the purchase of its first medical device company in that country. It picked up Guangzhou Bioseal Biotech for an undisclosed sum.
The report says spending on branded drugs in the U.S. increased 2.2% in actual dollars to $258 billion from $252 billion, based on data from IMS Health.
Analysts think St. Jude Medical ($STJ) and Edwards Lifesciences ($EW) could be eyed by Johnson & Johnson ($JNJ) as potential pickups.
Johnson & Johnson's Alex Gorsky hung up his hat in the CEO office today. He'll also have to roll up his sleeves.
Resolving manufacturing problems so Johnson & Johnson can get its once well-regarded consumer brands back in consumers hands is Alex Gorsky's first priority as he officially takes the reins as CEO today.
Expect Johnson & Johnson ($JNJ) to start spending some of its $14 billion in cash on medical device deals to help expand its presence in emerging markets once Alex Gorsky becomes CEO.
In reporting an 8% first-quarter earnings decline to shareholders, Novartis acknowledged the company's inability to meet GMPs at a variety of plants played a big role in that dip.
The American Business Council has warned authorities that they had better get the matter sorted out or the country will soon face shortages.
It took a year after the initial announcement, but Johnson & Johnson ($JNJ) finally gained European regulatory approval for its $21.3 billion bid to buy Synthes.
In the face of a sluggish economy barely recovering from its historic collapse in 2008, almost all of the companies made a concerted effort to boost their R&D spending during their 2011 fiscal years.